Stocks To Watch Today: Oracle Corporation (ORCL) And Pfizer Inc. (PFE) On The Marquee

The price of Oracle Corporation (NYSE:ORCL) went down by -$2.07 now trading at $46.68. Their shares witnessed a 9.65% increase from the 52-week low price of $42.57 they recorded on 2018-06-20. Even though it is still -14.57% behind the $53.48 high touched on 2018-03-13. The last few days have been rough for the stock, as its price has decreased by -3.13% during the week. It has also performed poorly over the past three months, as it lost around -2.16% while it has so far retreated around -2.73% during the course of a year. The stock of ORCL recorded -1.27% downtrend from the beginning of this year till date. The 12-month potential price target for Oracle Corporation is set at $52.93. This target means that the stock has an upside potential to increase by 13.39% from the current trading price.

When giving their opinion, around 45.71% of Wall Street analysts, which represents 16 out of 35 rated the stock as a Buy. 18 brokerage firms of the remaining 51.43% rated the stock as a Hold with 1 analyst rating it as a sell. Overall, the number of aggregate ORCL shares held by institutional investors represents 58% of total shares. 107 institutions entered new Oracle Corporation (NYSE:ORCL) positions, 577 added to their existing positions in these shares, 998 lowered their positions, and 91 exited their positions entirely.

Oracle Corporation (ORCL) trade volume has increased by 108.33% as around 39,780,863 shares were sold when compared with its 50-day average volume of traded shares which is 19,095,018. At the moment, ORCL is witnessing a downtrend, as it is trading -5.15% below its 20-day SMA, -4.67% below its 50-day SMA, and -2.69% below its 200-day SMA. The company runs an ROE of roughly 8.3%, with financial analysts predicting that their earnings per share growth will be around 8.16% per annum for the next five year. This will be compared to the 2.4% increase witnessed over the past five years.

The first technical resistance point for Oracle Corporation (NYSE:ORCL) will likely come at $47.75, marking a 2.24% premium to the current level. The second resistance point is at $48.82, about 4.38% premium to its current market price. On the other hand, inability to breach the immediate hurdles can drag it down to $44.58, the lower end of the range. ORCL’s 14-day MACD is -0.35 and this negative figure indicates a downward trading trend. The company’s 14-day RSI (relative strength index) score is 40.28, which shows that its stock has been neutral. The 20-day historical volatility for the stock stands at 32.11 percent, which is high when compared to that of the 50-day’s 26.67 percent.

The shares of Pfizer Inc. (NYSE:PFE) has decreased by -0.35%, and now trading at $44.98 on the Wall Street in the intra-day deal, with their shares traded now around 29,951,109. This is a rise of 6,252,162 shares over the average 23,698,947 shares that were traded daily over the last three months. The stock that is trading at $44.98 went higher by 35.48% from its 52-week low of $33.2 that it attained back on 2018-02-09. The stock recorded a 52-week high of $46.47 nearly 3 days ago on 2018-12-04.

PFE stock has performed well over the past 30 days, as it added 3.35% while its price climbed by 24.19% year-to-date (YTD). Looking at the last few days, it has been good for the stock, as it rose 0.18% over the last week. The stock’s 12-month potential target price is now at $44.15. This means that the stock price might likely increase by -1.85% from its current trading price.8 out of 18 Wall Street analysts which represents 44.44% rated the stock as a buy while the remaining 44.44 rated it as a hold, with 11.11 of analysts rating it as a sell.

Pfizer Inc. (NYSE:PFE) has been utilizing an ROE that is roughly 33.7%, with stock analysts predicting that the company’s EPS for the next five years will go up by 7.42% per year, following the 10.4% raise that was witnessed during the past five years. The stock at the moment is on a uptrend, trading 2% above its 20-day SMA, 2.3% above its 50-day SMA, and 14.48% above its 200-day SMA. In percentage terms, the aggregate Pfizer Inc. shares held by institutional investors is 74.2%. 125 institutions jumped in to acquire Pfizer Inc. (PFE) fresh stake, 946 added to their current holdings in these shares, 1140 lowered their positions, and 56 left no stake in the company.

The stock’s 9-day MACD is 0.56 and this positive figure indicates an upward trading trend. The company’s 9-day RSI score is 55.75, which shows that its stock has been neutral. The 20-day historical volatility for the shares stand at 18.64 percent, which is less when compared to that of the 50-day’s 23.59 percent. On the daily chart, we see that the stock could reach the first level of resistance at $45.44, sporting a 1.01% premium to the current level. The next resistance point is at $45.9, representing nearly 2% premium to the current market price of Pfizer Inc. (PFE). On the other hand, failure to breach the immediate hurdles can drag it down to $43.15, the lower end of the range.